Angion Biomedica (Angion Biomedica) Debt-to-Asset : 0.01 (As of Mar. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Debt-to-Asset?

Angion Biomedica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.23 Mil. Angion Biomedica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.07 Mil. Angion Biomedica's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2023 was $41.77 Mil. Angion Biomedica's debt to asset for the quarter that ended in Mar. 2023 was 0.01.

Angion Biomedica Debt-to-Asset Historical Data

The historical data trend for Angion Biomedica's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica Debt-to-Asset Chart

Angion Biomedica Annual Data

Trend

Dec12

Dec13

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.91

1.19

0.05

0.07

Angion Biomedica Quarterly Data
	Jun13	Dec13	Mar14	Jun14	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Asset	Get a 7-Day Free Trial															0.06	0.06	0.07	0.07	0.01

Competitive Comparison of Angion Biomedica's Debt-to-Asset

For the Biotechnology subindustry, Angion Biomedica's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Angion Biomedica's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angion Biomedica's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Angion Biomedica's Debt-to-Asset falls into.

Angion Biomedica Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Angion Biomedica's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.061	+	2.649)	/	52.79
	=	0.07

Angion Biomedica's Debt-to-Asset for the quarter that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.227	+	0.07)	/	41.767
	=	0.01

Angion Biomedica (NAS:ANGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Angion Biomedica Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Angion Biomedica (Angion Biomedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459

Website

https://www.angion.com

Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Executives

Jay Venkatesan	director, officer: See Remarks	C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson	director	601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes	officer: See Remarks	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi	director
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc	10 percent owner	C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553